Loading
A phase 3 trial of Ibritumomab tiuxetan in Follicular lymphoma, run by Fondazione Italiana Linfomi - ETS, completed.
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) is a phase 3 interventional study registered as NCT01827605 by Fondazione Italiana Linfomi - ETS, with 159 participants recorded, started 2012-01 and reaching its primary completion in 2019-10. Interventions recorded: ZEVALIN, BEAM. Conditions recorded: Relapsed Follicular Lymphoma.
Linked to the drug Ibritumomab tiuxetan because the registry names it among its interventions and Follicular lymphoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ibritumomab tiuxetan and the tag pipeline.
Shares Fondazione Italiana Linfomi and the tag pipeline.
Shares Ibritumomab tiuxetan and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/